Insulin prices have risen rapidly over time, making costs a major public health concern. Understanding annual spending net of discounts—rather than the list price, which does not reflect amount paid—may inform strategies to contain insulin-related spending. We examined trends in U.S. per-beneficiary spending on insulin from 2008 to 2017, including pre- and post-discount expenditures by payer type and out-of-pocket costs.
Patiëntvoorbeelden m.b.t. vergoeding
- ten laste van verzekeraar
- geen vergoeding door verzekeraar